Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Sarcoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

anlotinib 2penpulimab 1Temozolomide 1Ritonavir 1Radiotherapy 1Indinavir 1Catecholamines 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Pheochromocytoma × anlotinib × Clear all
NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
10 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05133349 2021-11-24

EASOAIPPGL

Nanjing First Hospital, Nanjing Medical University

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡